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Abstract
Background: Polydrug abuse is a known problem among opioid-dependent patients receiving opioid maintenance
treatment (OMT). However, improved laboratory diagnostics is required to reveal polydrug abuse in its current scope.
Furthermore, there are few studies focusing on the relationship between polydrug abuse and adequacy of the dose of
OMT medicine. This study aimed to evaluate the polydrug abuse among opioid-dependent patients receiving OMT
with inadequate (Group IA) and adequate (Group A) doses of OMT medicine as experienced by the patients. Craving
for opioids and withdrawal symptoms were evaluated as indicators of the adequacy rating.
Methods: This is a retrospective register-based study of 60 OMT patients on either methadone or sublingual
buprenorphine/naloxone medication, whose polydrug abuse was studied from urine samples by means of a
comprehensive high-resolution mass spectrometry method.
Results: Inadequate doses of the OMT medicines were associated with higher subjective withdrawal scores
and craving for opioids. Six groups of abused substances (benzodiazepines, amphetamines, opioids, cannabis,
new psychoactive substances, and non-prescribed psychotropic medicines) were found among OMT patients.
Group IA patients showed significantly more abuse of benzodiazepines and amphetamines than the Group A
patients. All the new psychoactive substances and most of the non-prescribed psychotropic medicines were
detected from the Group IA patients. There was no difference in the doses of the OMT medicine between
Groups IA and A patients.
Conclusions: Polydrug abuse, detected by definitive laboratory methods, was widespread and more common
among Group IA than Group A patients, emphasizing the requirement for individual OMT medicine dose adjustment.
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Background
Maintenance treatment for opioid dependence (OMT), ei-
ther with methadone or buprenorphine-based medications,
improves retention in the treatment and reduces abuse of
illicit opioids [1]. Many OMT studies have targeted patients
with heroin dependence and cocaine abuse [2, 3]. However,
in Finland the most commonly abused opioid is buprenor-
phine, and the most commonly abused stimulant is am-
phetamine [4]. Consequently, the results concerning
heroin-dependent patients may not be applicable to the
Finnish OMT patients. Yet, OMT does not prevent poly-
drug abuse. Polydrug abuse during OMT is a significant
problem based on surveys [4, 5] and on studies relying on
standard immunoassay screening [6]. Broad-spectrum
polydrug abuse includes not only traditional illicit drugs,
but also non-prescribed psychotropic medicines (N-PPM)
and new psychoactive substances (NPS) [1, 7]. For the first
time, the data concerning NPS reports for 2015 [7] dis-
closes a wide range of substances (e.g. fentanyl derivates
and benzodiazepines) not belonging to any of the major
groups identified in previous years. The abuse of BZD
among OMT patients is worldwide, with a reported preva-
lence of 45% in France and 70% in Germany [8], 51% in
Israel [9], 47% in the USA [10], and 38% in Australia [11].
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Polydrug abuse for its part decreases retention in OMT
[12], and the decreased retention is related to the degree of
severity of polydrug abuse [13].
Most NPS and many N-PPM are not detectable by con-
ventional urine immunoassays, but a broad range of these
new abused drugs, in addition to traditional illicit drugs,
can be revealed by comprehensive urine drug-screening
methods based especially on liquid chromatography-high-
resolution time-of-flight mass spectrometry (LC-TOFMS)
[14]. Using this type of urine analysis, polydrug abuse, in-
cluding NPS and N-PPM, has also been reported among
OMT patients [15–18]. The LC-TOFMS method has
proved to be specific and sensitive, providing a scope
and reliability beyond standard immunoassay, without
the necessity for a subsequent quantitative confirm-
ation analysis [14].
Both methadone and buprenorphine in fixed doses are
effective in suppressing illicit opioid use [2, 19–21].
Fixed-dose studies do not require individualized dose
levels because of retention in treatment, and treatment
outcomes. However, fixed doses are rarely used in clin-
ical practice as the flexible dosing of the medicine is
more relevant to patient care [22, 23]. Contrary to fixed
dose studies, flexible dose studies suggest that the opti-
mal dose of the OMT medicine should be tailor-made
and differ between patients, to account for differences in
severity of addiction, chronicity, main substance of de-
pendence, method of administration, potency of main
opioid used, tolerance acquired, and idiosyncratic issues.
While numerous reports indicate that the co-abuse of
opioids and BZD is ubiquitous around the world, the
reasons for the co-abuse of these medications are not
entirely clear [24]. Besides the desire to become intoxi-
cated [25], craving and withdrawal symptoms associated
with the abused drug are certainly essential causes of co-
abuse. Furthermore, a significant relationship has been
found between inadequate doses of the OMT medicines
experienced by the OMT patients and their BZD-
positive urine samples [26]. Although the LC-TOFMS
method used in this finding [26] was capable of detect-
ing N-PPM and NPS, those compounds were not found
at that time.
The emergence of new abused substances on the mar-
ket markedly affects the therapy circumstances of OMT
patients [1, 7]. However, studies focusing on polydrug
abuse taking advance of definitive laboratory methods
are few. In this study, our first objective is to evaluate
the polydrug abuse among OMT patients, including
NPS and N-PPM in addition to traditional illicit drugs,
by means of comprehensive LC-TOFMS urine screening.
Our second objective is to assess whether polydrug
abuse is related to the adequacy of the dose (adequate or
inadequate) of the OMT medicine as experienced by the
patients.
Methods
Procedure
This is a retrospective register-based study for which the
data was collected from medical files between November
2015 and January 2016 at the outpatient clinic for
opioid-dependent patients of the Helsinki University
Central Hospital (HUCH). The clinic is a specialized ter-
tiary addiction psychiatry clinic for opioid-dependent pa-
tients who have different psychiatric and somatic
comorbidities. Before starting the OMT, all opioid-
dependent patients had at least one unsuccesful trial for
withdrawal from opioids at some other clinic than at the
outpatient clinic for opioid-dependent patients of
HUCH. The occurrence of comorbid psychiatric disor-
ders and substance dependencies of the patients (the
DSM-IV, Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition) [27] are shown in Table 1.
Since our previous study [26], the routine medical files
of the clinic have included self-reports regarding sub-
stance abuse, withdrawal ratings, cravings, and for expe-
rienced adequacy of the dose of the OMT medicine. The
rating for dose adequacy can be too low (the dose if in-
sufficient), adequate (the dose if sufficient), too high, or
unsure, according to the patient’s opinion. In routine
clinical practice, the trough blood concentration of
(R,S)-methadone was analyzed, but no quantification of
buprenorphine in blood was carried out. The routine
medical files also included both conventional urine im-
munoassays for abused drugs taken from one to four
times per month and urine LC-TOFMS analysis taken
usually once per month. A two-month period for this
retrospective study was considered sufficient to obtain
one urine LC-TOFMS analysis result from each of the
OMT patients. The inclusion criteria for patients were
as follows: the dose adequacy rating was either inad-
equate (Group IA) or adequate (Group A); the urine
sample for LC-TOFMS analysis was collected maximally
3 days after the above-mentioned clinical assessments;
and the blood sample for methadone quantification was
collected the next day after the clinical evaluations.
Sixty of the 85 different patients (71%) fulfilled the
above-mentioned criteria.
The institutional Review Board of the Department of
Psychiatry, HUCH, approved the study protocol, which
was conducted in accordance with the ethical guidelines
set forth by the Declaration of Helsinki.
Clinical assessments
The opioid withdrawal symptoms as experienced by the
patient were based on the short, 10-item withdrawal
scale (SOWS) [28] which rates the severity of each with-
drawal symptom on a four-point scale, including zero,
one, two and three: where zero equals ‘not at all’ and
three equals ‘severe’ (range 0–3). The objective rating of
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withdrawal symptoms was based on the 13-item OOWS
scale [29] which indicates each withdrawal symptom on
a two-point scale (zero and one): where zero equals ‘ab-
sence of any symptom’, and one equals ‘presence of a
symptom’. The craving for opioids during the preceding
24 h was based on the visual analog scale (VAS). This
study used a single-item VAS rating for the evaluation of
craving for opioids: where zero equals ‘none’ and 10 equals
‘very much’. The rating of the withdrawal symptoms and
the rating of the craving for opioids were included as po-
tential indicators of the dose adequacy rating.
Thirty-five patients in Group IA, and 17 patients in
Group A, carried hepatitis-C but none of the patients
had received medication for the disease. One Group A
patient had HIV infection which was medicated with
Triumeq (dolutegravir/abacavir/lamivudine). Neither the
patients with hepatitis-C, nor those with HIV infection,
were medicated with opioids or gabapentinoids. None of
the patients had any advanced kidney disease which
would have indicated medications.
Laboratory analyses
All patient urine samples were collected under supervision
(a one-way mirror), and laboratory analyses were carried
out blinded to the patients’ clinical condition. Urine drug
screening was performed using the LC-TOFMS method
[14]. The in-house LC-TOFMS database included approxi-
mately 700 compound entries, including traditional illicit
drugs, commonly abused N-PPM, and various classes of
NPS, such as non-medical benzodiazepines, synthetic can-
nabinoids, cathinones, opioids, phenethylamines, pipera-
zines, and tryptamines. A reference standard was available
for 400 compounds while the remaining entries were rare
NPS and their known or predicted metabolites, for which a
reference standard was unavailable. Typical reporting limits
in urine for the substances studied were as follows: 50 or
100 ng/mL for BZD, 100 ng/mL for amphetamines,
100 ng/mL for the cocaine metabolite benzoylecgonine,
10 ng/mL for cannabis, 20 ng/mL for NPS, 1 ng/mL for
buprenorphine, and 50 ng/mL for other opioids.
Among the following psychotropic medicines, pre-
scribed by the attending physicians for the study pa-
tients at the out-patient clinic for opioid-dependent
patients of HUCH, the LC-TOFMS database included
quetiapine but did not include agomelatine, aripiprazole,
clozapine, doxepin, escitalopram, fluoxetine, lamotrigine,
lithium, melatonin, mirtazapine, olanzapine, paliperidone,
risperidone, sertindole, valproate, venlafaxine, or ziprasi-
done. Gamma-hydroxy butyrate was not analysed due to
its very short elimination half-life.
Trough methadone concentrations in serum were de-
termined by gas chromatography – mass spectrometry
(GC-MS) in selected ion monitoring mode following
liquid-liquid extraction. The limit of quantification
(LOQ) was 100 ng/mL, and the expanded uncertainty of
measurement was 11%.
Table 1 Psychiatric comorbid disorders and substance dependences at the start of opioid maintenance treatmenta
Total
(n = 60)
Inadequate dose,
n = 39 (65.0%)
Adequate dose,
n = 21 (35.0%)
Number of groups of comorbid psychiatric disorders 1.3 ± 0.70 (0–3) 1.28 ± 0.69 (0–3) 1.33 ± 0.73 (0–3)
Schizophrenia and other psychotic disorder 30 (50.0%) 19 (31.7%) 11 (18.3%)
Mood disorder 9 (15.0%) 5 (8.3%) 4 (6.7%)
Anxiety disorder 10 (16.7%) 6 (10.0%) 4 (6.7%)
Disorders usually first diagnosed in Infancy, Childhood, or Adolescenceb 2 (3.3%) 2 (3.3%) 0 (0%)
Eating disorderc 1 (1.7%) 1 (1.7%) 0 (0%)
Personality disorder 26 (43.3%) 17 (28.3%) 9 (15.0%)
Number of groups of non-opioid drug dependences 1.40 ± 0.89 (0–3) 1.41 ± 0.85 (0–3) 1.38 ± 0.97 (0–3)
Non-opioid drug dependency 51 (85.0%) 35 (58.3%) 16 (26.7%)
Sedative-, hypnotic-, or anxiolytic-related disorderd 38 (63.3%) 25 (41.7%) 13 (21.7%)
Amphetamine 19 (31.7%) 13 (21.7%) 6 (10.0%)
Cocaine 0 (0%) 0 (0%) 0 (0%)
Alcohol 12 (20.0%) 6 (10.0%) 6 (10.0%)
Cannabis 6 (10%) 2 (3.3%) 4 (6.7%)
Medications 0 (0%) 0 (0%) 0 (0%)
Polysubstance-related disordere 3 (5.0%) 3 (5.0%) 0 (0%)
aAll diagnoses are made according to the DSM-IV. There were no statistically significant differences between the two groups of patients
bOne patient with Mild Mental Retardation and one patient with Attention-Deficit/Hyperactivity Disorder
cOne patient with Bulimia Nervosa
dTwo patients with pregabalin dependence
ePolysubstance-related disorder was rated as three
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Evaluation of polydrug abuse
Evaluation of the polydrug abuse was carried out accord-
ing to the DSM-IV. DSM-IV groups the abused substances
as follows: 1. alcohol; 2. amphetamine or similarly acting
sympathomimetics; 3. caffeine; 4. cannabis; 5. cocaine; 6.
hallucinogens; 7. inhalants; 8. nicotine; 9. opioids; 10.
phencyclidine (PCP) or similarly acting arylcyclohexyl-
amines; 11. sedatives, hypnotics, and anxiolytics; 12. poly-
substance abuse; and 13. other abused substances. The
positive urine findings by LC-TOFMS were divided fol-
lowing the DSM-IV into six groups of abused substances:
1. amphetamines; 2. BZD corresponding to the sedatives,
hypnotics, and anxiolytics group; 3. cannabis; 4. opioids;
and 5. NPS and N-PPM belonging to the other
abused substance group. The amphetamines group in-
cluded the common abused substances amphetamine,
methamphetamine, 3, 4- methylenedioxymethamphe-
tamine (MDMA, ecstasy), and methylphenidate. The
cannabis group consisted of 11-nor-9-carboxy-tetra-
hydrocannabinol (THC-COOH), which is the main metab-
olite of tetrahydrocannabinol (THC). The NPS group
substances met the criteria for NPS valid during the study
[30] as follows: NPS are substances of abuse, either in a
pure form or a preparation, that are not controlled by the
1961 Single Convention on Narcotic Drugs or the 1971
Convention on Psychotropic Substances, but which may
pose a public health threat. The term ‘new’ does not neces-
sarily refer to new inventions–several NPS were first syn-
thesized 40 years ago–but to substances that have recently
become available on the market. After the study, in April
2016, UNDOC placed alpha-pyrrolidinovalerophenone
(alpha-PVP) under international control [30].
The N-PPM group included those substances which
are not controlled under the Finnish narcotics legislation
and were not prescribed by physicians of HUCH, ac-
cording to the updated electronic database used by both
the psychiatric and somatic units of the hospital. The
positive urine samples for prescribed medicines were ex-
cluded from the study, comprising the 14 urine samples
positive for quetiapine and two urine samples positive
for oxazepam. All those medicines were prescribed by
the physicians of the outpatient clinic for opioid-
dependent patients. The use of N-PPM was against the
written patient contract given by all the study patients.
According to that contract, patients were not denied the
use of any medication that is indicated by their somatic
disease, but they had to inform the attending physician
of the out-patient clinic for opioid-dependent patients of
HUCH. We also studied the available self-reports of the
patients concerning their abuse of the N-PPM group
medicines. The available data showed that pregabalin
was abused in five cases, gabapentin in one case, and bu-
propion in one case. We were unaware as to whether
the medicines were prescribed by a physician who was
not working at HUCH, whether they were diverted, or
whether they were illegally imported to Finland. Any
substance included in the above groups had to be backed
by some published evidence concerning its abuse poten-
tial. We also included the unambiguous metabolites of
the substances. A positive result for any abused sub-
stance was always based on the positive urine finding by
LC-TOFMS and not on self-reports by the patients.
OMT medicines
Methadone patients received Methadone Martindale
Pharma 2 mg/mL oral solution (Martindale Pharmaceu-
ticals Limited, Romford, UK). Buprenorphine patients
received a Suboxone buprenorphine-naloxone sublingual
tablet containing buprenorphine and naloxone at a ratio
of 4:1 (Reckitt Benckiser Healthcare Ltd., Slough, UK).
Psychosocial treatment
A case management approach providing medical ser-
vices, community services, and counselling was offered
to all patients by the staff of the clinic. As an integrated
service, the comorbid psychiatric disorders were treated
by the two psychiatrists of the clinic.
Statistical analysis
Data was reported as the mean ± SD, minimum-
maximum values. Two group comparisons were per-
formed with Fisher’s Exact Test for nominal variables
and with the T-test for Equality of Means (equal vari-
ances not assumed) for continuous variables. The corre-
lations were calculated with the Pearson rank
correlation. The tests were two-tailed. The significance
level was set at alpha = 0.05. The analyses were per-
formed with SPSS version 22.
Results
Group IA included 39 (65.0%) patients, and Group A in-
cluded 21 (35.0%). Neither the gender (F 23.3%) nor the
age of the patients (35.4 ± 7.8, 20–56 years) were differ-
ent between Group IA and A patients (13.3% vs.10.0%
and 35.3 ± 7.8, 20–56 years vs. 35.8 ± 8.0, 22–54 years,
respectively). At baseline, 56 (93.3%) of the patients had
a comorbid psychiatric disorder and 51 (85.0%) of the
patients had a non-opioid drug dependency (Table 1).
There were no differences in the number of the psychi-
atric comorbid disorders nor non-opioid drug depen-
dences between Group IA and A patients.
The data of the OMT medicines is shown in Table 2.
The number of methadone and buprenorphine/naloxone
patients was different between Groups IA and A
(p = 0.002). No dosage differences for the OMT medicines
were evident between Groups IA and A. Similarly, no dif-
ference in blood concentration of methadone was de-
tected between Groups IA and A. The blood
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concentration of methadone was not available for the HIV
infected patient medicated with the combination of
dolutegravir/abacavir/lamivudine. This study did not find
any patients whose opioid or gabapentinoid medications
would have affected the methadone blood concentrations.
The duration of the OMT was shorter in Group IA
than in Group A (74.9 ± 75.7, 8–264 weeks vs.
236.3 ± 343.6, 16–512 weeks, p = 0.046). There was no
correlation between the duration of OMT and polydrug
abuse regarding the number of groups of abused sub-
stances (r = −0.070).
Table 3 demonstrates that the scores for SOWS and
for craving were higher in Group IA patients than in
Group A patients (p = 0.001 and p < 0.001, respectively)
but there was no difference in the OWS scores.
Table 4 shows that Group IA patients had significantly
more positive urine samples for abused substances than
Group A patients (51.7% vs.13.3%, p = 0.002). The num-
ber of groups of abused substances was greater in Group
IA patients than in Group A patients (2.0 vs 0.9,
p = 0.005). Both the BZD and amphetamine-containing
urine samples were more often positive in Group IA pa-
tients than in Group A patients (40.0% vs. 8.3%,
p = 0.007 and 35.0% vs. 6.7%, p = 0.013, respectively).
There were 17 (28.3%) urine samples which were positive
for both BZD and amphetamines. Fifteen of these samples
were provided by Group IA patients and two were pro-
vided by Group A patients (p = 0.019). The three
buprenorphine-positive urine samples were provided by
the methadone patients. Group A patients provided no
methamphetamine-, fentanyl-, NPS-, gabapentin-, quetia-
pine- or methylphenidate-positive urine samples but these
were all detected in Group IA patients’ samples.
Table 5 shows the data for the patients receiving daily
methadone doses less than 60 mg and for those receiv-
ing daily buprenorphine doses less than 16 mg. Among
these patients, all urine samples positive for abused sub-
stances were privided by Group IA patients.
Discussion
Polydrug abuse
This study found widespread polydrug abuse among
OMT patients as 65% of the urine samples tested posi-
tive for abused drugs via LC-TOFMS analysis (Table 4).
Abused substances were found in all six studied groups
of drugs, in order of decreasing occurrence: BZD (48%),
amphetamines (42%), cannabis (30%), N-PPM (25%),
NPS 8%, and opioids (7%). Polydrug abuse, in terms of
the number of groups of abused substances, was signifi-
cantly more common among Group IA patients than
among Group A patients. Group IA patients had more
positive urine samples for abused drugs (52% vs.13%),
more BZD-positive urine samples (40% vs. 8%) and more
amphetamine-positive urine samples (35% vs. 7%) than
Group A patients. All the NPS-positive samples, con-
taining alpha-PVP, MPA (methiopropamine), and PV8
(alpha-PHPP, alpha-pyrrolidinoheptiophenone), were
provided by Group IA patients. Most of the N-PPM-
positive urine samples, containing pregabalin, gabapen-
tin, and quetiapine, were from Group IA patients. In
addition, Group IA patients experienced more subjective
withdrawal symptoms and cravings for illicit opioids as
potential indicators for the dose-adequate rating. Neither
the doses of the OMT medicines, nor the methadone
blood concentrations, were different between the two
groups of patients.
Table 2 The maintenance treatment medicines
Total sample
(n = 60)
Inadequate dose
(n = 39)
Adequate dose
(n = 21)
p
Methadone / Buprenorphine –
naloxone sublingual tablet
52 (86.7%) / 8 (13.3%) 38 (63.3%) /1 (1.7%) 14 (23.3%) /7 (11.7%) 0.002
Dose of methadone (mg) 64.81 ± 13.6 (20–90) 65.0 ± 11.4 (20–90) 64.3 ± 18.6 (24–90) NS
Blood concentration of methadone
(mg/L) (n = 45)a
0.20 ± 0.1 (0.09–0.47) 0.19 ± 0.07 (0.09–0.36) N = 35 0.24 ± 0.10 (0.12–0.47), N = 10 NS
Dose of buprenorphine (mg) 14.8 ± 5.01 (6–20) 16.0 14.6 ± 5.4 (6–20) NS
aIn case the methadone blood concentration was <0.10 mg/L, the value was rated as 0.09 mg/L
Table 3 Withdrawal symptoms and craving for opioids
Total sample
(n = 60)
Inadequate dose
(n = 39)
Adequate dose
(n = 21)
p
SOWSa 8.8 ± 5.9 (0–24) 10.4 ± 6.1 (0–24) 5.8 ± 4.1 (0–18) 0.001
OOWSb 0.8 ± 1.4 (0–5) 1.0 ± 1.6 (0–5) 0.5 ± 0.9 (0–3) NS
Craving for opioidsc 3.8 ± 2.7 (0–10) 4.7 ± 2.7 (1–10) 2.1 ± 1.6 (0–5) < 0.001
aThe short opiate withdrawal scale, range 0–30
bThe objective rating on withdrawal symptoms, range 0–13
cThe craving for opioids during the preceding 24 h on visual analog scale, range 0–10
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The 40% occurrence of BZD-positive urine samples
among patients with inadequate doses is almost the
same (38%) as in our previous study among a similar
group of OMT patients [26]. At baseline, 42% of Group
IA patients of the present study had a sedative-, hyp-
notic, or anxiolytic related disorder, whereas 90% of the
patients in our previous study [26] had either BZD abuse
or dependence at the baseline. These findings do not ex-
clude the possibility that methadone treatment may
trigger the onset or worsening of BZD abuse as pointed
out by Chen et al. [10]. Group IA patients also demon-
strated significant co-abuse of BZD and amphetamines.
Regarding individual BZD drugs, oxazepam (38%), tem-
azepam (35%), and desmethyldiazepam (28%) were those
most commonly found. The number of urine samples
positive for abused temazepam and oxazepam would have
been lower if these compounds had been considered the
metabolites of diazepam. Diazepam has a higher abuse
Table 4 Polydrug abuse based on LC-TOFMS urine analysesa
Total sample
(n = 60)
Inadequate dose
(n = 39)
Adequate dose
(n = 21)
p
Positive urine samples 39 (65.0%) 31 (51.7%) 8 (13.3%) 0.002
Number of groups of abused substances 1.6 ± 1.5
(0–4)
2.0 ± 1.5
(0–4)
0.9 ± 1.4
(0–4)
0.005
BZD-positive 29 (48.3%) 24 (40.0%) 5 (8.3%) 0.007
Oxazepam 23 (38.3%) 19 (31.7%) 4 (6.7%) 0.029
Temazepam 21 (35.0%) 17 (28.3%) 4 (6.7%) NS
Desmethyldiazepam 17 (28.3%) 15 (25.0%) 2 (3.3%) 0.019
Alprazolam 10 (16.7%) 9 (15.0%) 1 (1.7%) NS
Clonazepam 7 (11.7%) 6 (10.0%) 1 (1.7%) NS
Midazolam 3 (5.0%) 3 (5.0%) 0 (0%) NS
Nitrazepam 2 (3.3%) 1 (1.7%) 1 (1.7%) NS
Bromazepam 1 (1.7%) 1 (1.7%) 0 (0%) NS
Demoxepam 1 (1.7%) 1 (1.7%) 0 (0%) NS
Lorazepam 1 (1.7%) 1 (1.7%) 0 (0%) NS
Amphetamine-positive 25 (41.7%) 21 (35.0%) 4 (6.7%) 0.013
Amphetamine 25 (41.7%) 21 (35.0%) 4 (6.7%) 0.013
Methamphetamine 2 (3.3%) 2 (3.3%) 0 (0%) NS
Methylphenidate 1 (1.7%) 1 (1.7%) 0 (0%) NS
Cannabis-positive 18 (30.0%) 13 (21.7%) 5 (8.3%) NS
Opioid-positive 4 (6.7%) 3 (5.0%) 1 (1.7%) NS
Buprenorphine 3 (5.0%) 2 (3.3%) 1 (1.7%) NS
Norbuprenorphine 1 (1.7%) 1 (1.7%) 0 (0%) NS
Fentanyl 1 (1.7%) 1 (1.7%) 0 (0%) NS
NPS-positive 5 (8.3%) 5 (8.3%) 0 (0%) NS
Alpha-PVPb 2 (3.3%) 2 (3.3%) 0 (0%) NS
MPAc 1 (1.7%) 1 (1.7%) 0 (0%) NS
PV8d 3 (5.0%) 3 (5.0%) 0 (0%) NS
N-PPM-positivee 15 (25.0%) 12 (20.0%) 3 (5.0%) NS
Pregabalin 10 (16.7%) 8 (13.3%) 2 (3.3%) NS
Gabapentin 2 (3.3%) 2 (3.3%) 0 (0%) NS
Quetiapine 3 (5.0%) 3 (5.0%) 0 (0%) NS
Bupropion 2 (3.3%) 1 (1.7%) 1 (1.7%) NS
aLiquid chromatography coupled to high-resolution time-of-flight mass spectrometry (LC-TOFMS)
bAlpha-pyrrolidinovalerophenone
cMethiopropamine
da-PHPP or alpha-pyrrolidinoheptiophenone
eNon-prescribed psychotropic medicines
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liability than oxazepam [24, 31], and consequently it is
possible that many of the oxazepam-and temazepam-
positive urine samples of this study reflect the abuse of
diazepam.
Amphetamine-positive urine samples were found sig-
nificantly more often among Group IA patients (35%)
than Group A patients (7%). The importance of prescrib-
ing appropriate methadone dosages to indirectly reduce
cocaine use has been described in the study by Baumeister
et al. [32]. Their consideration is in line with the present
study concerning amphetamine. Group IA patients had
two methamphetamine-positive urine samples. An earlier
Finnish study found 21% methamphetamine-positive
urine samples among OMT patients with irregular attend-
ance to a harm reduction unit, but no methamphetamine-
positive urine samples among OMT patients with regular
attendance to drug treatment at a rehabilitation clinic
[16]. Regular visits to the clinic are inevitably related to
more adequate doses of the OMT medicine than irregular
visits. Cocaine is seen in the Finnish drug market [4], and
also among OMT patients [15, 16], infrequently. Those re-
ports are in line with the negative urine samples of this
study regarding the cocaine metabolite benzoylecgonine.
Most of the gabapentinoid (gabapentin and pregaba-
lin)-positive urine samples (17%) were found among
Group IA patients. Up to 32% pregabalin-positive urine
samples have been found among Finnish OMT patients
who irregularly attend drug treatment at a harm reduc-
tion unit [16]. Both gabapentin and pregabalin are ap-
proved for the management of neuropathic pain [33]
and it is possible that the abuse of those drugs is related
at least partly to control opioid withdrawal symptoms
such as pain, unrest, and sleeplessness, but also due to
the psychotropic effects of the gabapentinoids [17]. No
gabapentinoids prescribed for somatic diseases were
found in this study.
Extremely common misuse of quetiapine among clients
of a methadone maintenance program has been reported
by McLarnon et al. [34]. All the three quetiapine-positive
urine samples of the present study were provided by
Group IA patients. Quetiapine has been reported to
increase plasma concentrations of (R)-methadone [35].
No high-methadone blood concentrations were found in
the two methadone patients from our study, who abused
quetiapine. These patients demonstrated 0.17 mg/L and
0.29 mg/L methadone corresponding to the 80 mg and
74 mg daily doses, respectively.
The present study found five (8%) NPS-positive urine
samples which all were given by Group IA patients. The
synthetic cathinones PV8 and alpha-PVP, and the thio-
phene ring-based structural analog of methamphetamine
MPA, were found in three, two, and one sample, re-
spectively. PV8 appeared on the illicit drug market in
2013 as a candidate to replace MDPV [36]. No MDPV
was detected in this study, in contrast to our previous
studies among OMT patients [15, 26]. To our know-
ledge, this study represents the first report on the abuse
of PV8 among OMT patients.
Cannabis-positive urine samples (30%) were found
both in Group IA (22%) and in Group A (8%). The
present study detected only THC-COOH and no syn-
thetic cannabinoids, similar to previous Finnish studies
[15, 16], although the LC-TOFMS method used in those
studies is able to detect many synthetic cannabinoids.
The absence of synthetic cannabinoids is likely due to
the increased incidence of home growing of cannabis in
Finland [4].
Opioids (7%) were the most seldom-found group of
abused substances. Only 2% of urine samples were
opioid-positive among Group A patients. Similarly,
Finnish OMT patients with regular attendance for drug
treatment had 7% opioid-positive urine samples in
contrast to 21% opioid-positive urine samples if the
attendance of the OMT patients was irregular [16].
Thus, the primary task of OMT, to prevent abuse of
opioids, is well realized when the dose of the OMT
medicine is adequate and the OMT patients regularly
attend their clinic. However, the three buprenorphine
positive urine samples from patients in methadone
treatment are alarming because of potential severe
withdrawal symptoms caused by the interaction of
those substances.
Table 5 Polydrug abuse of the patients with low doses of the maintenance treatment medicine
Medicine Dose (mg) Adequacy of the dose of the medicine Blood concentration (mg/L) Abused substances based
on LC-TOFMS methoda
Methadone 20 Too low dose < 0.10 Alprazolam
Methadone 24 Adequate Not available No substances
Methadone 30 Adequate 0.17 No substances
Methadone 50 Too low dose < 0.10 Oxazepam, temazepam,
amphetamine, bupropion
Buprenorphine 6 Adequate Not available No substances
Buprenorphine 8 Adequate Not available No substances
aLiquid chromatography coupled to high-resolution time-of-flight mass spectrometry (LC-TOFMS)
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Doses of the OMT medicines and polydrug abuse
No differences were observed in the mean daily doses of
methadone or buprenorphine/naloxone between Group
IA and Group A patients, i.e., 65 mg vs. 64 mg and
16 mg vs. 15 mg, respectively. The 65 mg mean daily
dose of methadone in this study is at the recommended
level (60 – 100 mg) according to reported fixed high-
dose studies [19–21], but the mean 15 mg daily dose of
buprenorphine is somewhat lower than the minimum ef-
fective mean daily dose of buprenorphine (16 mg) in
terms of suppression of abuse of opioids among heroin-
dependent patients [2]. Nonetheless, smaller doses of
OMT medicines have also been effective in reducing
substance abuse. In a flexible dose study, Soyka et al.
[23] reported that the mean daily doses of 44–50 mg
methadone and 9–12 mg of buprenorphine were related
to a significant decrease in substance use. Furthermore,
concomitant drug use for all illicit substances decreased
with either an 8 mg or 10 mg daily dose of buprenor-
phine after 12 months in a non-interventional study per-
formed under real-life conditions [12]. The real life
conditions of the study by Apelt et al. [12] were similar
to those of the present study, where even 24 mg and
30 mg daily doses of methadone, and 6 mg and 8 mg
daily doses of buprenorphine, were adequate and urine
samples were negative for abused substances (Table 5).
Methadone blood concentration and polydrug abuse
No difference was evident in mean methadone trough
blood-concentration (0.20 mg/L) between Group IA
(0.19 mg/L) and Group A (0.24 mg/L) patients. Two
Group IA methadone patients receiving 20 mg and
50 mg daily doses had less than 0.10 mg/L methadone
blood concentrations (Table 5). Group IA also included
two other methadone patients (60 mg and 76 mg daily
doses) whose methadone blood-concentrations were less
than 0.10 mg/L. We found that a methadone concentra-
tion less than 0.10 mg/L is related to polydrug abuse,
thus higher methadone blood concentrations are needed.
The mean methadone concentration of this study was
lower than the 400 ng/mL reported by D’Aunno et al.
[21]. It is possible that somewhat higher methadone
blood-concentrations would have been combined with
less polydrug abuse. However, the blood concentration
of methadone has large interindividual variation for a
given dosage due to the interindividual variability of
CYP enzymes and interactions between methadone and
several medications [37]. In addition, both cannabis and
BZD can affect methadone blood concentrations [38].
Therefore, it is interesting that there is no evidence of a
greater variability in the blood concentrations of metha-
done among the patients with polydrug abuse and differ-
ent psychiatric comorbidities (Table 2).
Strengths and limitations
This study carries several limitations. The cross-sectional
design limits making causal and temporal conclusions be-
tween the dose adequacy and polydrug abuse among
OMT patients. In addition, the substance groups per def-
inition in some way may overlap and may share similar
features. Furthermore, the number of patients was rela-
tively small, giving rise to possible statistical type I and II
errors.
Regarding the OMT medicines, Group IA patients
were more often on methadone than Group A patients.
The patients were not randomized to methadone and
buprenorphine/naloxone medication at the start of the
OMT, and it is possible that patients with more severe
opioid dependence were started with methadone. In
addition, the total number of buprenorphine/naloxone
patients was low.
The occurrence of individual abused substances in
urine samples cannot be generalized because substance
abuse in different countries is highly variable and
dependent on both the area, the period of evaluation,
and the target population. The LC-TOFMS method was
limited by the content of the database used. Although
full high-resolution MS data were acquired, the data
analysis protocol mined only for the masses included in
the database. If any of the patients were using a drug
that is not targeted by the method, it is highly likely that
a false negative result would have been obtained. The
LC-TOFMS database of this study did not include olan-
zapine and venlafaxine which both possess abuse liability
[39]. However, this study shows that OMT patients
abuse a broad range of illicit and licit substances and it
is unlikely that this is only a Finnish feature among
OMT patients. Concerning the safety of the OMT, it is
important to give the OMT patients the correct infor-
mation regarding the abused substances because the pa-
tients are seldom aware of the actual substances they are
abusing [15]. The uncertainty of the patients concerning
their abused substances may partly be related to the psy-
chiatric comorbidities and to impaired memory among
methadone or buprenorphine patients using BZD [40].
Alcohol consumption was not controlled in this study. A
third of patients receiving OMT have been found to
have increased alcohol consumption and alcohol use dis-
orders [41]. Furthermore, a recent study by Preston et
al. [42] reports that drinking was associated with heroin
and cocaine craving and actual use among patients in
methadone maintenance treatment. Thus, the lack of
data concerning alcohol consumption is a clear limita-
tion of this study.
Group IA patients demonstrated moderately high mean
scores for opioid craving (4.7), whereas Group A patients
had quite low mean scores for craving (2.1) on the VAS-
scale. Craving may have different roles among those using
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various substances and craving contains both automatic
and cognition-controlled processes [43, 44]. The VAS-
scale may have measured global craving for drugs, al-
though the patients in the present study were advised to
focus only on craving due to illegal opioids as the patients
had much polydrug abuse and many psychiatric comor-
bidities. Besides the uncertainty of rating for craving fo-
cusing on only opioids, the rating of subjective withdrawal
symptoms may have been nonspecific to some extent, be-
cause BZD abuse may also exacerbate opioid-specific
withdrawal symptoms [45].
This study failed to consider the actual distress/symp-
toms related to the comorbid psychiatric disorders or the
licit psychotropic medicines prescribed by the attending
physicians. Although the occurrence of the drug depen-
dences and the comorbid psychiatric disorders at baseline
were not different between Group IA and Group A pa-
tients, the actual psychiatric syndrome and the licit psy-
chotropic medicines might have been different between
the two groups and consequently might have affected
polydrug abuse differently. This study cannot exclude the
possibility that some of the abused substances were actu-
ally targeted to treat some of the drug dependences or
psychiatric disorders. The more than 90% occurrence of
comorbid psychiatric disorders of this study by itself is
similar to the study of Brooner et al. [46]. Interestingly,
Brooner et al. [46] found that in methadone maintenance
treatment, reductions in psychiatric distress of the patients
were unrelated to substance use outcomes.
It is possible that there are important additional fac-
tors that are related to the dose adequacy rating and can
provide more information about polydrug abuse in
OMT. The scores of stability of sense of coherence were
similar at baseline and after 1 year among patients in
methadone maintenance treatment, but were lower
among patients who still abused any drugs compared
with patients who did not [47]. Thus, the relationship
between dose adequacy rating and the sense of coher-
ence rating would be an interesting topic in future stud-
ies on polydrug abuse among OMT patients.
Conclusions
This study detected widespread polydrug abuse among
OMT patients based on comprehensive LC-TOFMS
urine screening. Polydrug abuse was more common if
the dose of the OMT medicine was too low and thus in-
adequate as experienced by the patients answering a
simple questionnaire. Inadequate doses of the OMT
medicines were associated with higher subjective with-
drawal scores and craving for opioids which are potential
indicators for the dose adequacy rating. Additional
causes of polydrug abuse concerning different groups of
abused substances clearly merits future studies among
OMT patients.
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